Expert: Aducanumab Approval Creates Hope, New Opportunities for Patients with Alzheimer Disease

Pamela Spicer, senior analyst at Datamonitor with Informa Pharma Intelligence, said there are no other currently available treatments for Alzheimer disease that get to the root of the condition.

Although the FDA approval of aducanumab for the treatment of patients with Alzheimer disease and mild cognitive impairment has been debated, Pamela Spicer, senior analyst at Datamonitor with Informa Pharma Intelligence, said its approval is a momentous occasion for this patient population. Spicer said there are no other currently available treatments for Alzheimer disease that get to the root of the disease, so the approval of aducanumab gives patients much-needed hope.